Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/62350

TitleDevelopment, in vitro release and in vivo bioavailability of sustained release nateglinide tablets
Author(s)Venkatesh, D. N.
Meyyanathan, S. N.
Shanmugam, R.
Zielinska, A.
Campos, J. R.
Ferreira, J. D.
Souto, Eliana
KeywordsSustained release
Xanthan gum
Nateglinide
Oral bioavailability
Pharmacokinetics
Issue dateFeb-2020
PublisherElsevier
JournalJournal of Drug Delivery Science and Technology
CitationVenkatesh, D. N.; Meyyanathan, S. N.; Shanmugam, R.; Zielinska, A.; Campos, J. R.; Ferreira, J. D.; Souto, Eliana, Development, in vitro release and in vivo bioavailability of sustained release nateglinide tablets. Journal of Drug Delivery Science and Technology, 55(101355), 2020
Abstract(s)Purpose The scope of this work is the characterization of the behavior of polysaccharides, such as xanthan gum, as matrix-forming agent for the development of sustained release tablets containing nateglinide. Methods Conventional immediate release (IR) and sustained release (SR) tablets were produced by wet granulation and direct compression methodologies, respectively. FTIR analysis demonstrated no interactions between drug and excipients, as the physicochemical characteristics of bulk materials were kept in the formulated tablets. Results Fresh IR and SR tablets exhibited appropriate friability and hardness properties for transport and handling. Formulations composed of xanthan gum showed delayed release properties; while dependent on the polymer concentration, release followed the first order kinetics fitting to Fickian mathematical model. The optimized formulation was tested in six male albino rats for the comparison of the in vivo performance of IR and SR tablets. While oral bioavailability remained similar between both types of tablets, the pharmacokinetic parameters demonstrated the modified release profile of SR i.e. extended half-life (t1/2) and higher maximum time to peak (tmax), and decreased maximum plasma concentration (Cmax) and elimination rate (kel), contributing for longer-term treatments with this drug. Conclusions Sustained release tablets composed of xanthan gum have been successfully developed for the oral delivery of nateglinide.
TypeArticle
DescriptionSupplementary data to this article can be found online at https:// doi.org/10.1016/j.jddst.2019.101355.
URIhttp://hdl.handle.net/1822/62350
DOI10.1016/j.jddst.2019.101355
ISSN1773-2247
Publisher versionhttps://www.journals.elsevier.com/journal-of-drug-delivery-science-and-technology
Peer-Reviewedyes
AccessRestricted access (UMinho)
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_52159_1.pdf
  Restricted access
737,79 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID